Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Sponsor: Ottawa Hospital Research Institute
Summary
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.
Official title: The Impact of Adjuvant Androgen Deprivation Following Radical Prostatectomy on Prostate Cancer Recurrence
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2023-03-06
Completion Date
2028-11
Last Updated
2025-03-20
Healthy Volunteers
No
Conditions
Interventions
Lupron Depot
Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
Locations (3)
Nova Scotia Health
Halifax, Nova Scotia, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Centre universitaire de santé McGill - McGill University Health Centre
Montreal, Quebec, Canada